Preclinical News and Research

RSS

Human trial of second investigational Ebola vaccine candidate under way

Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health's Clinical Center in Bethesda, Maryland.

23 Oct 2014

Crown Bioscience announces U.S. expansion with new translational oncology center

Crown Bioscience, Inc., a leading global drug discovery and development service company, has announced the opening of the Crown Bioscience US Research Center to be located at the David H. Murdock Research Institute (DHMRI), in Kannapolis, N.C. The new center, which will open in the 3rd quarter of 2014, represents significant U.S. market expansion for Crown.

21 Oct 2014

Researchers propose new milestones to augment National Alzheimer's Plan

The U.S. Government has initiated a major effort to prevent and effectively treat Alzheimer's disease by 2025. However, a workgroup of nearly 40 Alzheimer's researchers and scientists says the research milestones in the U.S. Government's National Plan to Address Alzheimer's Disease must be broadened in scope, increased in scale, and adequately funded in order to successfully achieve this goal.

20 Oct 2014

New preclinical imaging product line launched by MILabs at the 2014 Annual European Association of Nuclear Medicine Meeting

MILabs BV has launched a complete new preclinical product line at the 2014 Annual European Association of Nuclear Medicine Meeting in Gothenburg, Sweden, October 18-22 (www.eanm.org). It consists of the new 4-series comprising U-SPECT4, U-SPECT4CT, VECTor4 and VECTor4CT incorporating significant improvements over the former PLUS-series. The 4-series carries even further the tradition of MILabs to deliver the best SPECT and PET image resolution available in the market.

20 Oct 2014

Researchers receive NIH grant to study mechanisms of auditory hypersensitivity in fragile X syndrome

Fragile X syndrome (FXS) is a genetic disorder in humans that causes social impairments and repetitive behaviors, and other behaviors on the autistic spectrum, as well as cognitive deficits.

17 Oct 2014

Mediso launches MultiScan LFER 150 PET/CT for research applications

Mediso announces the MultiScan LFER 150 PET/CT, the first member of the MultiScan product line dedicated to research applications for both clinical and pre-clinical imaging. The LFER 150 (Large Field of view Extreme Resolution) with 20 cm axial and 15 cm transaxial field of view (FOV), sub-mm PET resolution and 5% sensitivity is aimed at pre-clinical brain research.

17 Oct 2014

SOFIE BIOSCIENCES awarded NCI Phase II SBIR contract to develop [18F]FAC PET

SOFIE BIOSCIENCES, a leader in the field of Positron Emission Tomography (PET) imaging, including probes, scanners, and chemistry systems, announced today that the National Cancer Institute has awarded the company a Phase II Small Business Innovation Research (SBIR) contract for approximately $1.5M over two years.

16 Oct 2014

Researchers define the process of Parkinson's disease using genetic mouse model

Parkinson's Disease is the second most common neurodegenerative disorder. In Germany alone, almost half a million people are affected. The focus of the disease is the progressive degeneration of dopamine-producing nerve cells in a certain region of the midbrain, the substantia nigra. Misfolded proteins are the cause. Until recently, it was unclear why damage is confined to specific nerve cells.

16 Oct 2014

Researchers develop DNA-based drug delivery system that targets cancer cells

Biomedical engineering researchers have developed a drug delivery system consisting of nanoscale "cocoons" made of DNA that target cancer cells and trick the cells into absorbing the cocoon before unleashing anticancer drugs. The work was done by researchers at North Carolina State University and the University of North Carolina at Chapel Hill.

14 Oct 2014

Four UCLA researchers receive NIH Director's New Innovator Award

Four scientists from the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have received a National Institutes of Health Director's New Innovator Award that will forward revolutionary stem cell and neuro-science in medicine.

12 Oct 2014

Isis Pharmaceuticals provides update on Phase 2 clinical studies of ISIS-SMN Rx in children with SMA

Isis Pharmaceuticals, Inc. today provided an update on its ongoing open-label Phase 2 clinical studies of ISIS-SMN Rx in infants and children with spinal muscular atrophy at the 19th International World Muscle Society (WMS) Congress in Berlin, Germany.

10 Oct 2014

First study of promising Ebola vaccine commenced in West Africa

Professor Myron M. Levine, MD, Director of the Center for Vaccine Development at the University of Maryland School of Medicine, and UM SOM Dean E. Albert Reece MD, PhD, MBA, announced today that the CVD, in conjunction with its sister institution, The Center for Vaccine Development of Mali and the Ministry of Health of Mali, have begun a clinical trial in health care workers (and other front-line workers) to evaluate a promising experimental Ebola vaccine.

10 Oct 2014

Specific perceptual learning deficit associated with Fragile X Syndrome

Researchers at Children's Hospital Los Angeles have described for the first time a specific perceptual learning deficit in mice with a mutation of the same gene as found in children with Fragile X Syndrome (FXS).

9 Oct 2014

New drug discovery tool against Ebola virus

University of Utah biochemists have reported a new drug discovery tool against the Ebola virus. According to a study published in this week's online edition of Protein Science, they have produced a molecule, known as a peptide mimic, that displays a functionally critical region of the virus that is universally conserved in all known species of Ebola.

8 Oct 2014

Absorption Systems supports Pediatric Praziquantel Consortium led by Merck KGaA

Absorption Systems, a leader in preclinical contract testing of drugs, biologics, and medical devices, announces that it has been subcontracted by the German pharmaceutical company Merck KGaA to work on a new pediatric formulation of praziquantel.

7 Oct 2014

ERK and JNK enzymes may offer solutions for treating endometrial, colon cancers

In the quest to solve cancer's mysteries, they come in handy when describing tongue-twisting processes and pathways that somehow allow tumors to form and thrive. Two examples are ERK (extracellular-signal-related kinase) and JNK (c-June N-Terminal Kinase), enzymes that may offer unexpected solutions for treating some endometrial and colon cancers.

3 Oct 2014

Genoscience Pharma to present novel cancer therapeutic strategy at EORTC-NCI-AACR Symposium

Genoscience Pharma, a company focused on discovering and developing small molecules to treat cancer by targeting cancer stem cells, today announces that it will present data on its most promising candidate at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, in Barcelona, Spain, on November 18-21, 2014.

3 Oct 2014